1 in 3 AstraZeneca COVID vax trial participants reported adverse event
It appears side effects weren’t so rare after all, and AstraZeneca knows it. 

Mike Campbell

May 22, 2024

Data from AstraZeneca’s phase three trial results have recently become exposed, showing that within two years of receiving the shots, 1 in 3 participants reported suffering an adverse effect, and 1 in 35 experienced a “serious adverse event.”

1 in 3 AstraZeneca COVID vax trial participants reported adverse event

The Canadian Independent also reported the disturbing data, quietly released late November 2023.

21,587 trial participants received the actual AstraZeneca shots compared to 10,793 who received a placebo. The data follows participants for two years after they received their COVID vaccine in 2021.

Of the 21,587 who received the shots, 621 individuals reported a serious adverse event (SAE), which is over 3%. 

According to the data, “An SAE is an [Adverse Event] occurring during any study phase that fulfils 1 or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event.” 

Moreover, a staggering 4,750 participants out of the 21,587 reportedly required medical attention (MAAE) after receiving the vaccine, which is over 1 out of every 5 people who took the experimental product.

Finally, adverse events of special interest (AESI) were reported by 2,516 participants, which is about 1 in 9 people, and is classified as “events of scientific and medical interest specific to the further understanding of the study intervention safety profile and required close monitoring and rapid communication by the investigators to the sponsor.”

Comparatively, the placebo group had much smaller numbers in all three categories. Only 1.3% reported an SAE (compared to 3.2%), 11.6% reported a MAAE (compared to 22%), and 5.5% reported an AESI (compared to 11.6%). 

In all, of those who received the shots, more than 1 in 3 of AstraZeneca’s phase III trial participants reported an adverse event, compared to just less than 1 in 5 among the control group.

AstraZeneca pulls vaccines 

AstraZeneca recently pulled its COVID shots off the European market, just one month after admitting in court for the first time that the jabs can cause rare but devastating side effects.

Now, it appears these side effects weren’t so rare after all, and they know it. 

Share this story

Help Keep your News Free

Share this story

It's crucial we stay in touch

Big Tech wants to censor us, that’s why you need to stay in touch.

YOU MIGHT ALSO LIKE THESE...

Trending News

Conservatives flip one of the safest Liberal ridings in the country.

Mike Campbell

June 25, 2024

Trending News

The federally-funded Toronto Star, which once wrote “let them die” referring to unvaccinated people, published an article claiming Canadians haven’t lost any freedom.

Alexa Posa

June 21, 2024

Trending News

Following intense scrutiny from the mainstream media over a vaccine event hosted by the UCP, pro-vaccine scientists, doctors, and professors opted not to participate in a debate. 

Alexa Posa

June 18, 2024

Trending News

City Council is bringing in new restrictions, and crisis-level water rationing might become the new norm.

Keean Bexte

June 12, 2024

Trending News

The coercion and broken promises of COVID vaccines has consequences.

Mike Campbell

June 12, 2024

Trending News

PHAC commissioned a study to figure out how to increase vaccine uptake in babies, “even if [parents] perceive the risk of serious illness from COVID-19 to be low and the risk from a new vaccine to be high.”

Mike Campbell

June 11, 2024

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.